S. Puhalla

发表

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

Adrian V. Lee, P. Lucas, S. Oesterreich, 2017, JAMA oncology.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

Adrian V. Lee, P. Lucas, M. Nikiforova, 2015, Clinical Cancer Research.

Targeted mutation detection in breast cancer using MammaSeq™

Steffi Oesterreich, Yuri E Nikiforov, Marina N Nikiforova, 2019, Breast Cancer Research.

Targeted mutation detection in breast cancer using MammaSeq™

Adrian V. Lee, P. Lucas, M. Nikiforova, 2018, bioRxiv.

Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.

C. Shapiro, S. Puhalla, D. Young, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PARP inhibitors in breast cancer: BRCA and beyond.

S. Puhalla, Jorge Rios, J. Rios, 2011, Oncology.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

E. Winer, K. Hess, Minetta C. Liu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes

Adrian V. Lee, D. L. Taylor, S. Oesterreich, 2018, Oncology.

Recurrent hyperactive ESR 1 fusion proteins in endocrine therapy-resistant breast cancer

B. Leyland-Jones, P. Lucas, G. Frampton, 2018 .

Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer

A. Jager, M. Robson, M. Friedlander, 2017 .

Metastatic breast cancer patients: attitudes toward tissue donation for rapid autopsy

M. Rosenzweig, John W. Wilson, S. Puhalla, 2015, Breast Cancer Research and Treatment.

Nodal micrometastases in early stage breast cancer: two case reports

V. Vogel, S. Puhalla, J. Reeder, 2009 .

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2019, BMC Cancer.

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

B. Ramaswamy, C. Shapiro, X. Pan, 2014, Investigational New Drugs.

Bevacizumab in breast cancer: the best is yet to come?

A. Brufsky, S. Puhalla, 2009, Oncology.

Unsanctifying the sanctuary: challenges and opportunities with brain metastases.

L. Kleinberg, E. Neuwelt, L. Muldoon, 2015, Neuro-oncology.

Adjuvant endocrine therapy for breast cancer: don't ditch the switch!

N. Davidson, S. Puhalla, R. Jankowitz, 2011, Journal of the National Cancer Institute.

Phase I study of veliparib in combination with gemcitabine

A. Chen, L. Appleman, J. C. Schmitz, 2017, Cancer Chemotherapy and Pharmacology.

Triple-negative breast cancer: not entirely negative.

J. Leone, S. Puhalla, J. P. Leone, 2013, Oncology.

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers

H. Tawbi, E. Chu, S. Puhalla, 2013, Cancer Chemotherapy and Pharmacology.

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).

M. Buyse, K. Pogue-Geile, A. Srinivasan, 2018 .

Management of breast cancer brain metastases is moving forward, but new options are still needed.

S. Puhalla, S. Pahuja, 2014, Oncology.

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer

S. Puhalla, Karthik Kota, 2017, Cureus.

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2015, SpringerPlus.

Hematopoietic growth factors: Personalization of risks and benefits

N. Davidson, S. Puhalla, S. Bhattacharya, 2012, Molecular oncology.

Treatment of Metastatic Breast Cancer: Chemotherapy

S. Puhalla, S. Bhattacharya, 2016 .

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer

A. Brufsky, S. Puhalla, 2008, Biologics : targets & therapy.

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

J. O’Shaughnessy, A. Brufsky, S. Puhalla, 2016, Breast cancer.

Treatment of HER2-positive breast cancer: looking backwards briefly.

A. Brufsky, S. Puhalla, 2013, The Lancet. Oncology.

Should we embrace or ablate our urge to (ovarian) suppress?

N. Davidson, S. Puhalla, R. Jankowitz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study

N. Ibrahim, S. Kesari, M. Ahluwalia, 2016 .

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2020, The Lancet. Oncology.

A Case of Late-Onset Gemcitabine Lung Toxicity

A. Brufsky, S. Puhalla, A. Sherrod, 2011, Clinical Medicine Insights. Oncology.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

W. Gradishar, J. Garber, A. Jager, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2019, Annals of Oncology.

-refractory adult T-cell leukemia α load following alemtuzumab in AZT/IFN Durable hematological complete response and suppression of HTLV-1 viral

M. Caligiuri, J. Byrd, R. Baiocchi, 2013 .

Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.

V. Vogel, A. Brufsky, P. Rastogi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020, Clinical breast cancer.

RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.

J. Garber, A. D’Andrea, L. Moreau, 2015, The Journal of clinical investigation.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

J. Garber, Eric F. Johnson, M. Robson, 2016, Future oncology.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

E. Winer, N. Ibrahim, R. Gelman, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).

A. Chen, H. Tawbi, V. Giranda, 2015 .

Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

A. Chen, H. Tawbi, A. Tan, 2014 .

Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases

Adrian V. Lee, P. Lucas, S. Oesterreich, 2021, Journal of bone oncology.

The molecular landscape of premenopausal breast cancer

Adrian V. Lee, Serena G. Liao, G. Tseng, 2015, Breast Cancer Research.

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

M. Burgess, S. Puhalla, 2014, Front. Oncol..

A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

M. Goetz, M. Beeram, H. Burris, 2015 .

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Adrian V. Lee, B. Park, S. Oesterreich, 2017, Breast Cancer Research.

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

D. Dabbs, R. Bhargava, A. Brufsky, 2013, Modern Pathology.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

Adrian V. Lee, B. Leyland-Jones, M. Rosenzweig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

A. Chen, D. Gandara, T. Owonikoko, 2019, Cancer Chemotherapy and Pharmacology.

Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

A. Chen, H. Tawbi, A. Tan, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Larry Rubinstein, James H Doroshow, L. Rubinstein, 2012, Clinical Cancer Research.

Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets

George C Tseng, Steffi Oesterreich, Adrian V. Lee, 2018, Journal of the National Cancer Institute.

Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).

A. Chen, L. Appleman, E. Chu, 2015 .

A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.

A. Chen, T. Owonikoko, S. Ramalingam, 2012 .

Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors

H. Tawbi, L. Appleman, J. C. Schmitz, 2021, Cancer Chemotherapy and Pharmacology.

ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

N. Ibrahim, S. Kesari, M. Ahluwalia, 2020, Clinical Cancer Research.

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

H. Wildiers, M. Friedlander, B. Arun, 2021, Clinical Cancer Research.

Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.

H. Wildiers, M. Friedlander, B. Arun, 2021, European journal of cancer.

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

Adrian V. Lee, S. Oesterreich, A. Brufsky, 2016, Oncotarget.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal therapy in breast cancer: A model disease for the personalization of cancer care

N. Davidson, S. Puhalla, S. Bhattacharya, 2012, Molecular oncology.

Predictors of Pathologic Complete Response After Standard Neoadjuvant Chemotherapy in Triple-negative Breast Carcinoma

D. Dabbs, R. Bhargava, K. McGuire, 2012, Applied immunohistochemistry & molecular morphology : AIMM.

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2019, BMC Cancer.

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2014, Clinical breast cancer.

ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.

N. Ibrahim, S. Kesari, M. Ahluwalia, 2016 .

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

M. Caligiuri, J. Byrd, R. Baiocchi, 2005, Blood.

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Brian S. Roberts, R. Myers, Minetta C. Liu, 2020, Breast cancer research : BCR.

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.

S. Greenspan, A. Brufsky, B. Lembersky, 2016, Bone.

Breast cancer: The 21-gene recurrence score — biology remains at the forefront

N. Davidson, S. Puhalla, 2016, Nature Reviews Clinical Oncology.

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors

D. Dabbs, A. Soran, P. Mcauliffe, 2017, Modern Pathology.

Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?

D. Dabbs, A. Soran, P. Mcauliffe, 2018, American journal of clinical pathology.

Prevalence and determinants of end‐of‐life chemotherapy use in patients with metastatic breast cancer

M. Rosenzweig, A. Brufsky, S. Puhalla, 2017, The breast journal.

Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer

Adrian V. Lee, M. Nikiforova, Y. Nikiforov, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity.

M. Rosenzweig, A. Brufsky, P. Rastogi, 2011, Oncology nursing forum.

Adjuvant endocrine therapy for premenopausal women with breast cancer.

N. Davidson, A. Brufsky, S. Puhalla, 2009, Breast.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.

B. Ramaswamy, S. Puhalla, 2006, Drugs of today.

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood

Adrian V. Lee, N. Davidson, A. Brufsky, 2018, Scientific Reports.

Targeted mutation detection in breast cancer using MammaSeq™

Adrian V. Lee, M. Nikiforova, Y. Nikiforov, 2018, bioRxiv.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

S. Greenspan, A. Brufsky, B. Lembersky, 2015, Osteoporosis International.

Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With BRCA 1/2–Mutated Cancer or PARP‐Sensitive Tumor Types

V. Ivaturi, J. Gobburu, E. Chu, 2017, Journal of clinical pharmacology.

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study

Theresa A. Koleck, S. Sereika, Y. Conley, 2016, SpringerPlus.

Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer

D. Dabbs, P. Mcauliffe, R. Bhargava, 2018, American journal of clinical pathology.

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

C. Perou, E. Winer, J. Parker, 2014, Breast Cancer Research and Treatment.

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

E. Winer, Minetta C. Liu, R. Gelman, 2017 .

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

E. Winer, Minetta C. Liu, N. Ibrahim, 2014 .

Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: An independent study.

Adrian V. Lee, D. Dabbs, S. Oesterreich, 2014 .

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood

Adrian V. Lee, N. Davidson, A. Brufsky, 2018, Scientific Reports.

Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation.

M. Rosenzweig, A. Brufsky, B. Lembersky, 2014, Journal of Clinical Oncology.

Hematopoietic growth factors: personalization of risks and benefits.

N. Davidson, S. Puhalla, S. Bhattacharya, 2012, Molecular oncology.

Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer?

S. Sereika, S. Berga, C. Ryan, 2013, Menopause.

PARP inhibitors in breast cancer: BRCA and beyond.

S. Puhalla, J. Rios, 2011, Oncology.

Brian S. Roberts, R. Myers, Minetta C. Liu, 2020, Breast Cancer Research.

The molecular landscape of premenopausal breast cancer

Rohit Bhargava, George C. Tseng, Tianzhou Ma, 2015, Breast Cancer Research.

HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?

D. Dabbs, A. Soran, N. Davidson, 2016 .